OpGen (NASDAQ:OPGN) Earns Sell Rating from Analysts at StockNews.com

Equities research analysts at StockNews.com initiated coverage on shares of OpGen (NASDAQ:OPGN) in a research note issued to investors on Friday. The firm set a “sell” rating on the medical research company’s stock.

OpGen Stock Performance

OpGen stock opened at $4.17 on Friday. The stock’s 50-day moving average is $2.35 and its 200-day moving average is $1.70. OpGen has a 12 month low of $0.53 and a 12 month high of $6.30.

About OpGen

OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.